Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P55072: Variant p.Ile126Phe

Transitional endoplasmic reticulum ATPase
Gene: VCP
Feedback?
Variant information Variant position: help 126 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help US The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Isoleucine (I) to Phenylalanine (F) at position 126 (I126F, p.Ile126Phe). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (I) to large size and aromatic (F) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In IBMPFD1; uncertain significance. Any additional useful information about the variant.


Sequence information Variant position: help 126 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 806 The length of the canonical sequence.
Location on the sequence: help PDVKYGKRIHVLPIDDTVEG I TGNLFEVYLKPYFLEAYRPI The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         PDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPI

Mouse                         PDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPI

Rat                           PDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPI

Pig                           PDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPI

Bovine                        PDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPI

Xenopus laevis                PDVKYGKRVHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPI

Xenopus tropicalis            PDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPI

Zebrafish                     PDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPI

Drosophila                    PDVKYGKRVRILPIDESTEGVTGNLFEIYLKPYFLEAYRPI

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 806 Transitional endoplasmic reticulum ATPase
Mutagenesis 110 – 110 Y -> A. Abolishes interaction with NPLOC4; when associated with 52-A--A-55.
Mutagenesis 131 – 131 F -> R. Severely reduced binding to DERL1.
Mutagenesis 140 – 140 L -> D. Severely reduced binding to DERL1.
Beta strand 126 – 128



Literature citations
Nuclear inclusions mimicking poly(A)-binding protein nuclear 1 inclusions in a case of inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia with a novel mutation in the valosin-containing protein gene.
Matsubara S.; Shimizu T.; Komori T.; Mori-Yoshimura M.; Minami N.; Hayashi Y.K.;
Neuromuscul. Disord. 26:436-440(2016)
Cited for: VARIANT IBMPFD1 PHE-126;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.